About Zetagen Therapeutics
Zetagen Therapeutics is a private company based in Syracuse, New York. It has reported $26,108,382 raised in five offerings on Form D since February 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 31, 2025 | Jan 23, 2025amended Nov 12, 2025 | $12,908,022of $12.9M target | 35 | $368K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 29, 2022 | Feb 6, 2023 | $9,634,360of $15.0M target | 44 | $218K | EquityRule 506(b) | Form D ↗ |
| Dec 13, 2019 | Dec 27, 2019 | $840,000of $8.5M target | 4 | $210K | EquityRule 506(b) | Form D ↗ |
| Jul 13, 2018 | Dec 26, 2018 | $1,000,000fully sold | 30 | $33,333 | DebtRule 506(b) | Form D ↗ |
| Jan 28, 2017 | Feb 13, 2018 | $1,726,000fully sold | 47 | $36,723 | DebtRule 506(b) | Form D ↗ |
| Total, five offerings | $26,108,382 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Zetagen Therapeutics's Form D filed Nov 12, 2025.
JL
Joe Loy
Executive officer and director
RW
AK
Ashok Kaveeshwar
Director
PF
Peter Finn
Secretary
NM
Nikhil Thakur, MD
Executive officer and director
DB
Donald Brown
Director
Earlier filings also listed David Tischler (executive officer and director, last listed Dec 2018).